Annotation Detail
Information
- Associated Genes
- CDKN2A
- Associated Variants
-
CDKN2A p16 EXPRESSION
CDKN2A p16 EXPRESSION - Associated Disease
- head and neck squamous cell carcinoma
- Source Database
- CIViC Evidence
- Description
- In this retrospective analysis of the SPECTRUM trial, p16 (CDKN2A) expression (and HPV-infection) was not predictive of response to EGFR-targeted therapy in combination with chemotherapy (n = 416 patient tumors).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/694
- Gene URL
- https://civic.genome.wustl.edu/links/genes/14
- Variant URL
- https://civic.genome.wustl.edu/links/variants/272
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Head And Neck Squamous Cell Carcinoma
- Evidence Direction
- Does Not Support
- Drug
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 24577117
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | Resitance or Non-Reponse | false |